Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N²M² umbrella trial.

ABSTRACT: Advances in molecular understanding and diagnostic precision of glioblastoma enable the identification of key genetic alterations in a timely manner and, in principle, allow treatments with targeted compounds based on molecular markers. Here we report the results of the phase 1/2 umbrella trial NCT Neuro Master Match (N²M²), which evaluated targeted treatments in 228 patients with newly diagnosed glioblastoma without O6-methylguanine DNA-methyltransferase promoter hypermethylation. Stratification for treatment was conducted by a trial-specific molecular tumor board across five subtrials, each evaluating a targeted therapy-alectinib, idasanutlin, palbociclib, vismodegib or temsirolimus-selected according to the best-matching molecular alteration. Patients without match

SUBMITTER: Wick W 

PROVIDER: S-EPMC12532562 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature